Navigation Links
Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
Date:7/17/2008

at seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first commercial product, Zingo(TM), is available in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in two pivotal Phase 3 clinical trials to support an indication for the management of acute pain following orthopedic surgery. Adlea has been shown to reduce pain after only a single administration for weeks to months in multiple settings in mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, and our regulatory approval strategy for Adlea. Actual results may differ materially from thos
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
2. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
3. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
4. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Anesiva Defines Regulatory Pathway for Adlea with FDA
7. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
8. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
11. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... YORK , Aug. 27, 2014 ... new market research report is available ... Chinese Guidebook for Application and Approval ... Regulations to Practices (2014 Edition) ... Now, Chinese regulations ...
(Date:8/27/2014)... -- CVS Caremark (NYSE: CVS ) announced today ... MedStar Health, a leading health care system with ten ... Washington, DC , region, which will ... patients. Through this clinical affiliation, MedStar Health patients will ... chronic disease monitoring and wellness programs at CVS/pharmacy stores ...
(Date:8/27/2014)... 27, 2014 Amgen (NASDAQ: AMGN ... (FDA) has granted priority review designation for ivabradine for ... an oral drug that inhibits the I ... the body,s cardiac pacemaker. 1 Ivabradine works to ... contractility or ventricular repolarization. 1 Heart failure is ...
Breaking Medicine Technology:Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 5Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 6Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 7Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 8Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 9Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 10CVS Caremark Announces New Clinical Affiliation with MedStar Health 2CVS Caremark Announces New Clinical Affiliation with MedStar Health 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7
... 18, 2007 /PRNewswire-FirstCall/ -- Vical,Incorporated today announced that ... following interim analysis of data,from the first 41 ... an,angiogenesis product candidate using Vical's DNA delivery,technology. Based ... the trial had been achieved with statistical,significance and ...
... Primary Endpoint of Improvement in Overall,Survival, WESTMINSTER, ... Inc. today announced top line results from,ENRICH, ... Efaproxyn ,(efaproxiral) plus whole brain radiation therapy ... breast cancer. The study,failed to achieve its ...
Cached Medicine Technology:Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 2Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 3Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 4Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6
(Date:8/28/2014)... (PRWEB) August 28, 2014 Coveros, ... today announced that it has partnered with InfoZen ... the performance start date of 2/4/2014 with U.S. ... Homeland Security (DHS) agency that oversees lawful immigration ... Coveros and InfoZen will automate the integration and ...
(Date:8/28/2014)... On September 1st, the National Pediculosis Association ... The goal is to help families and entire communities ... and without exposures to risky pesticides. The NPA ... exposures to pesticides should be limited as much as ... are often trivialized in the media, which present only ...
(Date:8/27/2014)... August 28, 2014 Aeroflow Healthcare ... acquire as part of a strategic expansion of ... positioned for taking ownership of new businesses through ... economies of scale. , Last week, the company ... Hometown Respiratory to increase service in the High ...
(Date:8/27/2014)... The report provides market analysis of ... Range Finder, LIDAR, 3D scanner, Laser Weapon, Dazzlers, Laser ... Laser Altimeter) by Domain (Aerospace, Defense and Homeland Security) ... by MarketsandMarkets, and its application in the aerospace and ... Laser Systems market is expected to register a CAGR ...
(Date:8/27/2014)... August 28, 2014 Recently, BambooIndustry.com, an innovative ... has announced that new bamboo panels are now ... providing deep discounts for clients worldwide. All people that place ... discounted rate, from 10 to 30 percent off. , ... new panels. “At the moment, all our new and old ...
Breaking Medicine News(10 mins):Health News:Coveros Partners with InfoZen on USCIS Transformation Integration Award 2Health News:Head Lice Can Be a Public Health Opportunity 2Health News:Head Lice Can Be a Public Health Opportunity 3Health News:Head Lice Can Be a Public Health Opportunity 4Health News:Aeroflow Healthcare Seeks Strategic Acquisition Opportunities 2Health News:Military Laser Systems Market Worth $2.73 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Military Laser Systems Market Worth $2.73 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Military Laser Systems Market Worth $2.73 Billion by 2020 - New Report by MarketsandMarkets 4Health News:BambooIndustry.com: Cheap Bamboo Panels for Clients Worldwide Offered Online 2
... , MONDAY, Jan. 16 (HealthDay News) -- Lip ... talk, a new study reports. The finding challenges ... listening to people around them, according to the Florida Atlantic ... ways to diagnose autism spectrum disorders. Videos of women ...
... News) -- Children delivered by Cesarean section appear to be ... 3, a new study says. The findings support the ... than 37,000 participants in the Norwegian Mother and Child Cohort ... were delivered by planned or emergency C-section with those who ...
... (HealthDay News) -- The use of street drugs known as ... warns. It describes the first known case of necrotizing ... So-called bath salts are sold as synthetic powders that "often ... on Drug Abuse, which in February warned that injections might ...
... which is available free online at http://www.shef.ac.uk/FRAX/ , ... the world the online version alone is used to ... annually, with numbers growing steadily. The FRAX ... the input of Bone Mineral Density (BMD) values measured at ...
... a baseball game, the home plate umpire must instantaneously ... strike. In new research from the University of Chicago, ... these kinds of visual categories are encoded. While ... to quickly determine the category of a moving visual ...
... , SUNDAY, Jan. 15 (HealthDay News) -- When ... impulsive, saving less and borrowing more, according to a new ... when females are scarce, males become more competitive. They compete ... assistant professor of marketing at the Carlson School of Management ...
Cached Medicine News:Health News:Is Continued Lip-Reading an Early Sign of Autism? 2Health News:Children Born by C-Section at Slightly Higher Asthma Risk 2Health News:'Bath-Salts' Injection Leads to Flesh-Eating Disease 2Health News:Enormous growth in use of WHO Fracture Risk Assessment Tool 2Health News:Neural balls and strikes: Where categories live in the brain 2Health News:Neural balls and strikes: Where categories live in the brain 3Health News:Do Men Flash Cash to Find a Mate? 2
... monoclonal antibody based colorimetric test intended ... gonorrhoeae. The test requires less than ... heating or pretreatment. The test does ... cultures. GonoGen&trade II eliminates agglutination, guesswork, ...
... GonoGen™ is a monoclonal ... for the confirmatory identification of ... not require isolated, viable or ... specimen and two minute rotation, ...
Rapid Test Kit...
... a novel device for the growth ... and Neisseria meningitidis. This product ... is easily transportable as a self-contained ... and examine the growth of organisms ...
Medicine Products: